ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1

Figures & data

Table 1. Summary of enzastaurin studies in diffuse large B-cell lymphoma.

Study ID/title	Patients (n)	Ref.
H6Q-MC-JCAI A multicenter, nonrandomized, open-label, single arm, Phase II study of enzastaurin in patients with relapsed/refractory DLBCL	55	[18]
H6Q-M-S013 Open-label, single-arm, Phase II study of rituximab, gemcitabine and oxaliplatin plus oral enzastaurin as treatment for patients with relapsed DLBCL	68	[18]
H6Q-MC-S028 Open-label, randomized, Phase II study of R-CHOP plus enzastaurin vs R-CHOP in the first-line treatment of patients with intermediate and high-risk diffuse large B-cell lymphoma	101 (100 evaluable) 57 enzastaurin 43 placebo	[18]
H6Q-MC-JCBJ A Phase III study to investigate the prevention of relapse in lymphoma using daily enzastaurin	758 randomized 742 treated Enzastaurin 493 Placebo 249	[17]

DLBCL: Diffuse large B-cell lymphoma; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Figure 1. OS on RCHOP+enzastaruin vs R-CHOP alone in high-risk DGM 1+ patients for S028 study.

Figure 2. ENGINE study design.

Camicia R , WinklerHC, HassaPO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol. Cancer14, 207 (2015).

 PubMed Web of Science ®Google Scholar

Crump M , LeppaS, HabermannTet al. Randomized, double-blind, Phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J. Clin. Oncol.34(21), 2484–2492 (2016).

 PubMed Web of Science ®Google Scholar